1,721,085 research outputs found
Immuno-Pathogenesis of Chronic Inflammatory Skin Diseases: Novel Molecular Targets and Biomarkers
No full textChronic inflammation has a crucial pathogenetic role in many diseases, including cutaneous chronic inflammatory disorders, such as psoriasis, atopic dermatitis, hidradenitis suppurativa, and chronic urticaria [...]
Phototherapy of allergic contact dermatitis by narrow-band ultraviolet B
No full textPhototherapy with narrow-band ultraviolet B (NB-UVB) (peak at 311 nm) has been recently used for the treatment of some eczematous diseases, such as atopic dermatitis. It has been demonstrated that NB-UVB is as efficacious as broad-band UVB, but with less side effects. The efficacy of NB-UVB phototherapy in inhibiting both patch test response and contact dermatitis of the hands in 8 nickel sensitive patients was evaluated. Clinical scores showed a significant improvement (57%). Moreover, irradiated areas were less reactive than untreated skin to patch test with nickel sulphate 5%. No side effects were observed. These data suggest than NB-UVB should be considered as a possible therapy for allergic contact dermatitis
Interleukin-33: increasing role in dermatological conditions
No full textInterleukin-33 is a novel and an unconventional member of IL-1 family. It is an inflammation-induced factor with dual function exercising its role as an intracellular regulator of gene expression, as well as, an extracellular alarm mediator. It is a ligand for ST2, a heterodimeric membrane-bound receptor of the orphan IL-1 family receptor. Interleukin-33/ST2 signaling has been studied in a wide range of inflammatory skin conditions for its crucial role in immune responses and tissue homeostasis. In this review, we report the current knowledge regarding the complex biology of interleukin-33 and its function in the skin and in clinical settings
Dupilumab therapy reduces urinary biopyrrin levels in atopic patients: a new possible biomarker of oxidative status in atopic dermatitis
No full textBackground: Accumulating evidence suggests that oxidative stress is involved in the inflammatory process of atopic dermatitis (AD). Biopyrrins are the end products of the oxidative reaction of bilirubin with reactive oxygen species. The aim of our study was to explore the correlation between urinary biopyrrin levels and AD severity as well as to assess the possible modification of them in AD patients during biologic therapy with human monoclonal antibody dupilumab. Methods: For this purpose, 25 adult patients with moderate-severe AD who were candidates for dupilumab therapy independently from the study, and 15 healthy control subjects, matched by sex and age, were enrolled. Morning urine samples were collected from all study participants. For AD patients, a collection was planned before starting therapy with dupilumab (WO), after 8, 16, 52 weeks (W8, W16, W52, respectively), and two years (Y2) of treatment. The analysis of urinary levels of biopyrrins was performed by ELISA assay. Results: Our results demonstrated that urinary biopyrrin levels were significantly augmented in AD patients, and interestingly they correlated with disease severity. Furthermore, dupilumab therapy decreased levels of urinary biopyrrins in AD patients after eight and 16 weeks, maintaining the result after 52 weeks as well as after two years of treatment. The correlation analysis showed a statistically significant positive correlation between the urinary concentration of biopyrrins and EASI Index, circulating total IgE as well as plasma C reactive protein levels. Conclusions: Dupilumab therapy was able to ameliorate oxidative state in AD patients
- …
